Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Tundra lists 3 Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07746895

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.

Gender: All

Updated: 2026-08-05

4 states

C3 Glomerulopathy (C3G)
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
COMPLETED

NCT04572854

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-21

10 states

C3G
IC-MPGN
Renal Transplant
+9
ACTIVE NOT RECRUITING

NCT05809531

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

Gender: All

Ages: 12 Years - Any

Updated: 2026-04-02

16 states

C3G
IC-MPGN
C3 Glomerulopathy
+9